ライフサイエンスコーパス: folinic acid

1 l chemotherapy (oxaliplatin, 5-Flourouracil, folinic acid).

2 cells was unable to support growth in 15 pM folinic acid.

3 ate than wild-type L1210 cells when grown on folinic acid.

4 m(2) of irinotecan base) or fluorouracil and folinic acid.

5 accumulation of polyglutamylated species of folinic acid.

6 eficiency can be corrected by treatment with folinic acid.

7 175 mg) L-folinic acid or low-dose (25 mg) L-folinic acid.

8 ation of pyrimethamine with sulfadiazine and folinic acid.

9 e cycles of OxMdG [oxaliplatin 85 mg/m(2), l-folinic acid 175 mg, fluorouracil 400 mg/m(2) bolus, the

10 randomized to receive 12 weeks of high-dose folinic acid (2 mg kg(-1) per day, maximum 50 mg per day

11 methylcobalamin (2 times/wk) and 400 microg folinic acid (2 times/d) for 3 mo.

12 py (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6

13 eived either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, f

14 omly assigned the de Gramont regimen (n=303; folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2)

15 r IHA chemotherapy designed to be equitoxic (folinic acid 200 mg/m2, fluorouracil 400 mg/m2 over 15 m

16 to receive either intravenous chemotherapy (folinic acid 200 mg/m2, fluorouracil bolus 400 mg2 and 2

17 therapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.

18 ing the de novo folate biosynthesis pathway, folinic acid (5-CHO-THF) could no longer support the fol

19 ecDHFR, EC 1.5.1.3) as a binary complex with folinic acid (5-formyl-5,6,7,8-tetrahydrofolate; also ca

20 a common combination chemotherapy, FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) in a 3D pr

21 folate derivative 5-formyltetrahydrofolate (folinic acid; 5-CHO-THF) was discovered over 40 years ag

22 However, when plated in 15 nM folinic acid, a growth rate similar to FA3 cells was obs

23 ngly, flavivirus replication was restored by folinic acid, a thymidine precursor, in the presence of

24 utoantibody and treating them with high-dose folinic acid along with other interventions to lower the

25 indicated that FUEL is unable to metabolize folinic acid (also known as leucovorin or 5-formyltetrah

26 for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for tho

27 d ternary complexes with trimethoprim (TMP), folinic acid and coenzymes (NADPH/NADP(+)).

28 cits in a rat model that can be prevented by folinic acid and dexamethasone.

29 emcitabine therapy were randomly assigned to folinic acid and fluorouracil (FF) or oxaliplatin and FF

30 f cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered

31 Chemotherapy was FOLFOX (folinic acid and oxaliplatin followed by bolus and infus

32 f antidotes (ethanol or fomepizole and folic/folinic acid) and consideration of extracorporeal treatm

33 with positive isolated studies for creatine, folinic acid, and an amino acid combination.

34 oocyte(-1)), (2) inhibited by methotrexate, folinic acid, and folic acid (Ki = 0.84 micromol/L, 0.71

35 (FU) and oxaliplatin using the oxaliplatin, folinic acid, and FU (OFF) regimen.

36 ium containing dialyzed serum and 15 pM [6S]-folinic acid, and parental DC-3F cells were compared by

37 was significantly greater in those receiving folinic acid as compared with those receiving placebo, r

38 nificantly greater in participants receiving folinic acid as compared with those receiving placebo, r

39 ous small molecules (for example, pyridoxal, folinic acid, ATP, and AMP) also convert the solution of

40 targeted nutritional intervention trial with folinic acid, betaine, and methylcobalamin was initiated

41 and this blockade is effectively relieved by folinic acid, but not by folic acid, supplementation.

42 Folinic acid, but not folic acid, supplementation normal

43 herapy with gemcitabine or fluorouracil plus folinic acid can be offered.

44 These results indicate that folinic acid conversion by MTHFS is required for bacteri

45 Chemotherapy with fluorouracil and folinic acid could improve survival of patients with sta

46 (AO), the enzyme that produces 7-OH-MTX, but folinic acid did not.

47 ucturally related compounds (including DOPA, folinic acid, etc.) and 13 other compounds (such as carn

48 2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a

49 notecan in combination with fluorouracil and folinic acid extends survival with a manageable safety p

50 tin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for patients with

51 In this study, we used folinic acid (FA), N-phosphonacetyl-L-aspartic acid (PAL

52 ity, and effectiveness of the combination of folinic acid (FA)/fluorouracil (5-FU) followed by escala

53 Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolu

54 anguage impairment, treatment with high-dose folinic acid for 12 weeks resulted in improvement in ver

55 followed by pyrimethamine, sulfadiazine, and folinic acid for at least 4 weeks in combination with a

56 ration of treatment with both pyridoxine and folinic acid for patients with alpha-AASA dehydrogenase

57 Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved ove

58 r Children were significantly greater in the folinic acid group as compared with the placebo group.

59 ion group, 83 (58%) in the fluorouracil plus folinic acid group, and 73 (52%) in the gemcitabine grou

60 n patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse ev

61 s 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.0

62 Adjuvant chemotherapy with fluorouracil and folinic acid improves overall survival for resected carc

63 We sought to determine whether high-dose folinic acid improves verbal communication in children w

64 ecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.

65 d less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer

66 herapy with pyrimethamine, sulfadiazine, and folinic acid independent of the infection stage of the f

67 The complex with folinic acid indicates that this enzyme selectively acti

68 duced NF-kappaB suppression by thymidine and folinic acid indicates the role of the thymidylate synth

69 itive for these autoantibodies and high-dose folinic acid is beneficial in treating these children.

70 associated with the presence in MCDB 402 of folinic acid, known clinically as leucovorin, which is a

71 romising combination chemotherapy regimen of folinic acid (leucovorin), fluorouracil, irinotecan, and

72 cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxa

73 FOLFIRINOX (fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin)

74 tional intervention with methylcobalamin and folinic acid may be of clinical benefit in some children

75 The addition of methionine, folinic acid, methyl-B(12), thymidine, or dimethylglycin

76 s treated with single-agent methotrexate and folinic acid (MTX-FA; SIR, 0.7; 95% CI, 0.5 to 1.1) and

77 noliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monothera

78 can monotherapy (n=151), or fluorouracil and folinic acid (n=149).

79 o receive chemotherapy with fluorouracil and folinic acid (n=1622) or to observation (with chemothera

80 ge positive binding co-operativity) and DHFR.folinic acid.NADPH (large negative binding co-operativit

81 In contrast, for DHFR.folinic acid.NADPH, the DeltaDeltaG(o) values are genera

82 linic acid] than to FOLFOX (5-FU+oxaliplatin+folinic acid), not only between isogenic tumors but also

83 therapy were given fluorouracil and low-dose folinic acid only.

84 uracil (370 mg/m2) with high-dose (175 mg) L-folinic acid or low-dose (25 mg) L-folinic acid.

85 dard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of

86 intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gr

87 nous MTX (4 mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX administration.

88 (2) high-dose intravenous methotrexate with folinic acid rescue and continuing intrathecal methotrex

89 alated-dose intravenous methotrexate without folinic acid rescue during interim maintenance courses.

90 Folinic acid-responsive seizures and pyridoxine-dependen

91 These results demonstrate that folinic acid-responsive seizures are due to alpha-AASA d

92 Thus, folinic acid-responsive seizures are identical to the ma

93 n other anonymous individuals diagnosed with folinic acid-responsive seizures showed similar results.

94 two patients whose CSF showed the marker of folinic acid-responsive seizures, but who responded clin

95 Supplementing pregnant Folbp1+/- dams with folinic acid reversed this phenotype in nullizygous pups

96 Brain capillaries from S-folinic acid (SFA; 40 mg/kg)-treated PCFT-nullizygous mi

97 Treatments in Poisoning inhibitors and folic/folinic acid should be continued during extracorporeal t

98 Patients received either folic acid or folinic acid supplements (1 mg/day) from week 6 to week

99 omized to receive either daily folic acid or folinic acid supplements during an additional week of MT

100 ty to FOLFIRI [5-fluorouracil(FU)+irinotecan+folinic acid] than to FOLFOX (5-FU+oxaliplatin+folinic a

101 ion symptom inventories after treatment with folinic acid; the patient with low tetrahydrobiopterin a

102 ly ATP-dependent, irreversible conversion of folinic acid to 5,10-methenyltetrahydrofolate.

103 lowing treatment, we observed penetration of folinic acid to the core of spheroids and metabolism of

104 ffect size (Cohen's d=0.91), indicating that folinic acid treatment may be more efficacious in childr

105 mprovements in ASD symptoms with leucovorin (folinic acid) treatment have been reported in some child

106 uman restored both antifolate resistance and folinic acid utilization to FUEL.

107 ng methenyltetrahydrofolate synthetase FAU1 (folinic acid utilization).

108 n group, 143 patients to receive 20 mg/m2 of folinic acid via intravenous bolus injection followed by

109 noliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 mont

110 noliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15

111 he metabolic precursors, methylcobalamin and folinic acid, would improve plasma concentrations of tra